Skip to content

Advertisement

  • Review
  • Open Access

ZFAS1: a novel tumor-related long non-coding RNA

Contributed equally
Cancer Cell International201818:125

https://doi.org/10.1186/s12935-018-0623-y

  • Received: 12 June 2018
  • Accepted: 20 August 2018
  • Published:

Abstract

Long non-coding RNAs (lncRNA) are classified as a kind of RNA, which are longer than 200 nucleotides in length and cannot be translated into proteins. Multiple studies have demonstrated that lncRNAs are involved in various cellular processes, including proliferation, differentiation, cell death, and metastasis. In addition, aberrant expression of lncRNAs has been discovered in human tumors, where they function as either oncogenes or tumor suppressor genes. Among numerous lncRNAs, we focus on ZNFX1 antisense RNA 1 (ZFAS1), a well-known lncRNA that is aberrant overexpression in various tumors, including melanoma, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, colon cancer, and Hepatocellular carcinoma, in which it functions as oncogene. In contrast, ZFAS1 is downregulated in breast cancer, which may function as tumor suppressor gene. In this review, we provide an overview of current evidence concerning the role and potential clinical utilities of ZFAS1 in human cancers.

Keywords

  • Long non-coding RNA
  • ZFAS1
  • Diagnostic biomarker
  • Therapeutic target

Background

Cancer incidence and mortality are increasing each year, making cancer a major public health problem and the leading cause of death worldwide. It is reported that 4,292,000 new cancer cases and 2,814,000 cancer deaths are predicted to occur in China in 2015 [1] and 1,688,780 new cancer cases and 600,920 cancer deaths will occur in United States in 2017 [2]. Despite current advances in surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy, cancer remains a leading cause of death and constitutes an enormous burden worldwide [3, 4]. One of the reasons affecting the tumor prognosis was lacking of effective early diagnostic method before progression and effective prognostic indicator for guiding the clinical treatment. Therefore, identifying potential diagnostic and prognostic biomarkers for cancer patients to guide clinical decision is crucial and necessary.

Long noncoding RNAs (LncRNAs) are a class of non-protein coding RNA molecules with more than 200 nucleotides in length, which were considered as genomic “junk” and “noise” initially. Thanks to recent advances in sequencing technologies and large-scale genome sequencing projects, more and more lncRNAs have been recently identified in the genomes [58]. According to GENCODE analysis (http://www.gencodegenes.org) of the last version of the Ensembl human genome annotation (GRch38, version 24 from August 2015), 28,031 transcripts originating from 15,941 genes can be identified as lncRNAs [9]. Increasing evidences have demonstrated that lncRNAs actively participate in the development of human diseases through regulating the expression of their downstream targets [10, 11]. In tumorigenesis, lncRNAs could function as oncogenes or tumour suppressor genes [12, 13]. Pertinent to clinical practice, lncRNAs have been reported to serve as diagnostic or prognostic biomarkers or as therapeutic targets in many types of human cancers [14, 15]. ZNFX1 antisense RNA 1 (ZFAS1), an lncRNA originally identified a regulator of mammary development [16]. Subsequent studies also demonstrated that ZFAS1 expression is upregulated in many human malignancies, including glioma, lung, colon, liver, ovary and gastric cancers [17], but downregulated in breast cancer [16, 18, 19]. The present review summarizes the current studies of regulation mechanisms and functions of ZFAS1 in the initiation and progression of human cancers (Tables 1, 2).
Table 1

Functional characterization of ZFAS1 in various tumors

Tumor type

Expression

Functional role

Related gene

Role

References

Breast cancer

Downregulation

Tumor suppressor

[16, 19, 21, 22]

Glioma

Upregulation

Proliferation, migration invasion, cell cycle, EMT process

E-Cadherin, N-cadherin, Snail, MMP2, MMP9, Integrin β1, ZEB1, Twist, HES-1, NICD

Oncogene

[25, 26]

Colorectal cancer

Upregulation

Proliferation, cell cycle, invasion, apoptosis, EMT process

miR-484, p53, cyclin B1, PARP, ZEB1, E-cadherin, ZO-1, Vimentin, N-cadherin

Oncogene

[3033]

Gastric cancer

Upregulation

Proliferation, cell cycle, migration, apoptosis, EMT process

N-Cadherin, Vimentin, ZEB1, Snail, MMP14, Twist, E-cadherin, EpCAM, Cyclin D1, Bcl2, Bax, Slug,

Oncogene

[3739]

Hepatocellular carcinoma

Upregulation/downregulation

Proliferation, apoptosis, invasion, metastasis

ZEB1, MMP-14, MMP16, miR-9, miR-150

Oncogene/tumor suppressor

[41, 42]

Ovarian cancer

Upregulation

Proliferation, migration, chemoresistance

miR-150, Sp1

Oncogene

[45, 46]

Melanoma

Upregulation

Proliferation

Ki67, PCNA, CyclinD1

Oncogene

[47]

Non-small cell lung cancer

Upregulation

Oncogene

[48]

Osteosarcoma

Upregulation

Proliferation, invasion

miR-200b, miR-200c, BMI1, Sp1, ZEB2

Oncogene

[49]

Esophageal squamous cell carcinoma

Upregulation

Oncogene

[50]

Acute myeloid leukemia

Upregulation

Proliferation, apoptosis

Oncogene

[51]

Natural killer/T-cell lymphoma

Upregulation

Proliferation apoptosis, cell cycle

NF-kB, P53

Oncogene

[52]

ZFAS1 ZNFX1 antisense RNA 1, EMT epithelial–mesenchymal transition

Table 2

Clinical significance of ZFAS1 in various tumors

Cancer type

Clinicopathological features

References

Glioma

Advanced tumor stage and poor prognosis

[25, 26]

Colorectal cancer

Lymphatic invasion, advanced TNM stage, vascular invasion, poor prognosis

[3133]

Gastric cancer

Lymphatic invasion, advanced TNM stage, vascular invasion, poor prognosis

[38, 39]

Hepatocellular carcinoma

Intrahepatic invasion, extrahepatic invasion, poor prognosis

[41]

Ovarian cancer

Insensitivity of platinum-based chemotherapy

[45]

Melanoma

Tumor thickness, lymph node metastasis, advanced tumor stages, poor prognosis

[47]

Non-small cell lung cancer

Advanced tumor differentiation grade, lymph node metastasis, advanced TMN stage, poorer prognosis

[48]

Osteosarcoma

Poor prognosis

[49]

Esophageal squamous cell carcinoma

Advanced histological grade, advanced T stage, poor prognosis

[50]

ZFAS1: ZNFX1 antisense RNA 1, TNM tumor-node-metastasis

Discovery of ZFAS1

ZFAS1, located at chromosomal band 20q13.13, an lncRNA that transcripts from the antisense strand near the 5′-end of the protein-coding gene Znfx1, hosts three C/D box snoRNAs (SNORDs): Snord12, Snord12b, and Snord12c [16]. ZFAS1 was originally identified a regulator of alveolar development and epithelial cell differentiation in the mammary gland [16], subsequently studies showed ZFAS1 was aberrantly down-regulated in breast cancer tissues and cells [16, 18, 19]. Recent studies have demonstrated that ZFAS1 was overexpressed in various cancer tissues and cell lines, and promoted the cancer progression through affecting the phenotypes of cancer cells and molecular pathways.

ZFAS1 in various cancers

Breast cancer

Breast cancer is the most frequent malignancies in women worldwide in 2017 based on the latest report on American Cancer Society [2]. Although the improvement in early diagnosis and more effective therapeutic strategies have enhanced the survival rates in past decade, the tumor progression of recurrence and metastasis is still unavoidable [20], and the underlying mechanisms are still unclear. Therefore, it is imperative to explore and elucidate the underlying mechanism and identify new biomarkers for treatment of breast cancer.

The expression and function of ZFAS1 in breast cancer is different from that in other cancers. Askarian-Amiri et al. [16] reported ZFAS1 was overexpressed in the mammary gland and down-regulated in breast tumors. Zhang et al. [19] found ZFAS1 was negative or weakly expressed in breast cancer. Lee et al. [21] found ZFAS1 was downexpression in HER2-positive breast cancer cells. Fan et al. [22] revealed that ZFAS1 expression was significantly downregulated in breast cancer cell lines and ZFAS1 overexpression significantly suppressed cell proliferation, migration and invasion. These findings indicated that the ZFAS1 may be a tumor suppressor in breast cancer, and thus, may serve as a potential therapeutic target for patients with breast cancer. There is no any reports about the reason for its different role in breast cancer from other cancers until now. According to the present studies that ZFAS1 was a regulator of alveolar development and epithelial cell differentiation in the mammary gland, we speculated that downregulated ZFAS1 may inhibit breast alveolar development and epithelial cell differentiation, and lead to breast cancer. However, the accurate mechanisms need further study.

Glioma

Glioma is the most common and aggressive form of adult primary brain tumors, accounting for 80% of malignant brain tumors [23, 24]. Despite all surgical efforts in combination with chemo and radiotherapy, gliomas are still incurable, and the prognosis remains dismal. Undoubtedly, a deeper understanding of the molecular mechanisms of glioma initiation and progression, identifying novel biomarkers and therapeutic targets, will contribute to develop more effective therapy for glioma.

Gao et al. [25] found ZFAS1 was upregulated in glioma tissues and cell lines and higher ZFAS1 expression in glioma tissues was significantly correlated with advanced tumor stage and poor OS. Then, knockdown of ZFAS1 in glioma cell lines significantly suppressed proliferation, migration and invasion. Lv et al. [26] reported that ZFAS1 expression was markedly upregulated in glioma tissues and tightly correlated with clinical stage and shorter survival. Then they found knockdown of ZFAS1 in glioma cell lines could promote apoptosis, and inhibit cell proliferation, migration, and invasion. Furthermore, ZFAS1 silencing could result in cell cycle arrest at the G0/G1 phase in glioma cell lines. Taken together, these data showed ZFAS1 might act as a valuable prognostic biomarker and potential therapeutic target for glioma.

Colorectal cancer

According to the latest statistics, colorectal cancer (CRC) is the third most commonly diagnosed cancer in the United States [27] and the fifth most diagnosed cancer in China [1, 34]. Although the 5-year survival has improved in the rich countries during the past decades, it remained less than 50% in the most developing countries, including China [28, 29]. Therefore, identifying novel functional biomarkers for the early diagnosis in CRC patients are important for improved its survival.

Thorenoor et al. [30] reported ZFAS1 was significantly up-regulated in CRC tissues compared to paired normal colorectal tissues. Then, ZFAS1 silencing decreases proliferation and tumorigenicity of CRC cell lines through inducing G1-arrest of cell cycle. Wang et al. [31] found ZFAS1 expression was significantly upregulated in CRC tissues compared with adjacent noncancerous tissues, and was higher in metastatic tumor tissues than in corresponding primary CRC tumor tissues. In addition, they found higher ZFAS1 expression in CRC was positively correlated with lymphatic invasion, TNM stage and poorer prognosis. Moreover, they found knockdown of ZFAS1 inhibited the metastasis of CRC cell lines and mouse models of metastasis. Xie et al. [32] reported that ZFAS1 expression was significantly upregulated in CRC tissues and cell lines, higher ZFAS1 expression was significantly associated with Helicobacter pylori infection, lymph nodes metastasis, advanced TNM stage and poor overall survival of CRC patients. Then they found ZFAS1 inhibition could markedly suppress CRC cell lines proliferation and invasion both in cell lines and mouse models of proliferation and metastasis. Another study by Fang et al. [33] found ZFAS1 was up-regulated in colonic cancer tissues compared with adjacent mucosa, and its expression level was significantly correlated with TNM stage, vascular invasion, and lymph node metastasis. In addition, they found knockdown of ZFAS1 impeded proliferation, invasion, and promoted apoptosis of colonic cancer cell lines. The above data showed ZFAS1 might act as a valuable prognostic biomarker and potential therapeutic target for CRC.

Gastric cancer

Gastric cancer (GC) is one of the most common digestive malignant tumors and ranks as the second cause of death by malignancy worldwide [34, 35]. Although the progressive diagnosed methods and standard chemotherapy protocols have been established, prognosis of GC patients is still very poor [36]. Thus, there is still a pressing need to elucidate the molecular mechanisms underlying gastric cancer progression, as well as to identify key biomarkers and develop effective targeted therapies.

Zhou et al. [37] reported ZFAS1 was up-regulated in both tissues and plasmas of GC patients, as well as GC cell lines compared with paired normal tissues, plasmas or normal gastric cell lines. Another study by Nie et al. [38] reported that ZFAS1 was overexpressed in GC tissues, and its increased level is associated with shorter survival. In addition, knockdown of ZFAS1 impaired proliferation and induced apoptosis of GC cell lines, and inhibited the tumorigenicity of GC cells in mice. Pan et al. [39] found ZFAS1 expression was elevated in tumor tissues, serum and serum exosomes of GC patients and GC cell lines. Then, the increased ZFAS1 expression was significantly correlated with lymphatic metastasis and TNM stage. ZFAS1 knockdown inhibited the proliferation and migration of GC cell lines. On the contrary, ZFAS1 overexpression promoted the proliferation and migration of GC cells. Moreover, they found ZFAS1 was present in exosomes and could be transmitted by exosomes to enhance proliferation and migration of GC cell lines. These data indicated ZFAS1 may be involved in regulation of EMT in GC progression, ZFAS1 might serve as a potential biomarker and/or therapeutic target for GC.

Hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most prevalent and aggressive malignancies worldwide [35], with incidence rates continuing to increase rapidly [2]. In many cases, HCC is diagnosed at an advanced stage, which limits treatment options and affects prognosis [40]. So it is urgent to seeking new effective biomarkers for early diagnosis and effective therapy of HCC.

Li et al. [41] reported that ZFAS1 was frequently amplified in HCC, and associated with intrahepatic and extrahepatic metastasis and poor prognosis of HCC. Another study by Wang et al. [42] found ZFAS1 was markedly downregulated in HCC tissues and cell lines and overexpression of ZFAS1 inhibited the proliferation and induced the cell apoptosis in HCC cell lines. These data suggested ZFAS1 may be as a new prognostic biomarker and target for clinical management of HCC.

Ovarian cancer

Ovarian cancer is one of the most common and lethal gynecological malignancies [43]. Despite the advances in the treatment such as surgical technique, chemotherapy regimens and radiotherapy, the 5-year survival rate of ovarian cancer is still not satisfied [44]. So, it is imperative to elucidate the molecular mechanism of this disease and identify the biomarkers for treatment of ovarian cancer.

Xia et al. [45] reported ZFAS1 was upregulated in epithelial ovarian cancer tissues, and higher expression of ZFAS1 was correlated to poorer prognosis of patients with epithelial ovarian cancer. Then, they found ZFAS1 play a critical role in promoting the proliferation, migration, and chemoresistance of epithelial ovarian cancer cell lines. They further found ZFAS1 promoted proliferation, migration, and chemoresistance of epithelial ovarian cancer. Liu et al. [46] found higher expression of ZFAS1 was significantly associated with insensitivity of platinum-based chemotherapy by the analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Furthermore, they found the ZFAS1 expression was upregulated in cisplatin treated ovarian cell lines. These findings suggested that ZFAS1 serve as novel markers, therapeutic targets and participating in platinum resistance in ovarian cancer.

Other cancers

In recent days, some studies also reported that ZFAS1 plays a vital role in other cancers such as melanoma, non-small cell lung cancer (NSCLC), osteosarcoma (OS), esophageal squamous cell carcinoma (ESCC), acute myeloid leukemia (AML) and natural killer/T cell lymphoma (NKTCL).

Wei et al. [47] reported that the expression of ZFAS1 was significantly increased in melanoma tissues compared to adjacent non-cancerous tissues. They found the higher ZFAS1 expression were correlated with tumor thickness, lymph node metastasis, tumor stages in poor disease-free survival time (DFS) or over survival (OS) of melanoma patients. Then, knockdown of ZFAS1 by siRNAs suppressed melanoma cell line proliferation. Tian et al. [48] reported ZFAS1 was upregulated in NSCLC tissues, and higher expression in more advanced tumor tissues. Then, they found higher ZFAS1 expression were significantly associated with advanced tumor differentiation grade, lymph node metastasis, advanced TMN stage and a poorer prognosis. Liu et al. [49] found the expression of ZFAS1 was significantly overexpressed in OS tissues and cell lines, and upregulation of ZFAS1 was significantly associated with unfavorable prognosis of OS patients. They further found that ZFAS1 enhanced the growth and metastatic ability of OS cell lines and growth and metastatic model of mice. Shi et al. [50] reported ZFAS1 expression was significantly upregulated in ESCC tissues compared with the corresponding adjacent normal tissues. ESCC patients with higher ZFAS1 expression had a advanced histological grade, T stage and a poor prognosis. In addition, they developed a nomogram integrated clinicopathological factors and ZFAS1, could accurately predicted the prognosis of lymph node-negative ESCC patients without preoperative chemoradiotherapy. Guo et al. [51] reported ZFAS1 was upregulated in AML cell lines compared with T lymphocytic leukemia cell line or Burkitt’s lymphoma cell line, then they found knockdown of ZFAS1 impeded proliferation, and promoted apoptosis of AML cell line. Baytak et al. [52] found ZFAS1 was overexpressed in NKTCL tissues and ZFAS1-associated genes are enriched in pathways regulating proliferation and survival. The above data showed ZFAS1 might act as a valuable prognostic biomarker and potential therapeutic target for Melanoma, NSCLC, OS, ESCC, AML and NKTCL.

Regulatory mechanisms of ZFAS1 in human cancers

Overexpression of ZFAS1 in various cancers has been shown to exert oncogenic functions through regulating cancer-related phenotypes, such as promoting cell proliferation, migration, invasion, inhibiting apoptosis in different cancer types (Table 1). The mechanism by which ZFAS1 mediates such actions is complex and involves multiple factors (Fig. 1).
Fig. 1
Fig. 1

The regulatory mechanisms of ZFAS1 in human cancers

Promotion of epithelial–mesenchymal transition (EMT)

As we know, EMT is deemed to be the essential process of cancer progression, enhancing tumor migration and invasion [5355]. During the EMT process, epithelial cells lose epithelial status, apicobasal polarity and cell–cell adhesion so as to transform into mesenchymal cells [56, 57]. Positive regulation of EMT, manifested as down-regulation of epithelial markers (e.g. E-cadherin) and up-regulation of mesenchymal markers (e.g. vimentin), by knockdown of ZFAS1 has been demonstrated in glioma, colorectal cancer and gastric cancer. These data indicate ZFAS1 may be key activator of EMT process. However, how ZFAS1 regulate the notch signaling, direct or indirect, is unknown until now.

Activation of notch signaling pathway

The functions of notch signaling are commonly played in cooperation with other pathways during tumorigenesis. Previous study has showed that notch signaling is associated with EMT for cancer progression [53]. Gao et al. [25] found knockdown of ZFAS1 affected the expression of the notch signal-related proteins including HES family bHLH transcription factor 1 (HES-1) and notch intracellular domain (NICD), which indicate ZFAS1 may be another key activator of notch signaling. However, how ZFAS1 activates the notch signaling, direct or indirect, is unknown until now.

Regulation of proliferation, invasion and metastasis related genes

Just as we know, proliferation-related gene such as Ki67, PCNA, Cyclin B1, CyclinD1, PARP, Bcl2 and Bax, invasion and metastasis related genes such as MMP2, MMP9 and MMP14 play the key role in tumorgenesis and progression. It has been demonstrated that ZFAS1 could regulate the expression of above gene, thus promote the tumorgenesis and progression of various cancers such as melanoma, glioma, colorectal cancer and gastric cancer [26, 30, 37, 47]. However, whether these effect are direct or indirect, is unknown until now.

Acting as competing endogenous RNA (ceRNA)

Competing endogenous RNA (ceRNA) is a novel regulatory mechanism whereby lncRNAs function as ceRNA to sponge microRNAs (miRNAs) and regulate their downstream signaling pathways has been proposed and confirmed preliminarily [58, 59]. It was demonstrated that ZFAS1 exerted as ceRNA to enhance the expression of proliferation, invasion and metastasis related genes, such as ZEB1, MMP-14, MMP16, BMI1, Sp1 and ZEB2 by competitively sponging miR-150, miR-200b or miR-200c [41, 49], which indicated ZFAS1 became a new lncRNA functioning as ceRNA in cancer.

Other mechanisms

Wang et al. [42] found miR-9 was lowly expressed in HCC tissues and positively correlated with ZFAS1 expression. Meanwhile, significant downregulation of the methylation of CpG island in miR-9 promoter and upregulation of miR-9 expression were observed when ZFAS1 was overexpressed in HCC cell lines. Nie et al. [38] found that ZFAS1 could simultaneously interact with enhancer of zeste homolog 2 (EZH2) and lysine specific demethylase (LSD1)/REST corepressor-1 (CoREST) to repress the transcription of kruppel-like factor2 (KLF2) and naked cuticle 2 (NKD2) transcription by RNA immunoprecipitation and RNA pull-down experiment in GC cell line. Moreover, Liu et al. [49] found that SP1 functions as an upstream activated factor of ZFAS1 in osteosarcoma.

Conclusions and future perspectives

Since its discovery, ZFAS1 have been widely investigated in various human malignancies. ZFAS1 is upregulated and plays an oncogenic role in most types of tumors. However, ZFAS1 is downregulated in breast cancer, and may function as a tumor suppressor. Such discrepancy might be caused by distinct gene expression backgrounds in different tumors. In addition, the function of ZFAS1 in HCC is controversial, which needing further study. The mechanisms by which ZFAS1 mediates its actions is complex and involves multiple factors, including sponge action of miRNA, the effect on EMT, and the effect on cell cycle and apoptosis (Fig. 1). However, relatively little is known about the mechanism mediating upregulation of ZFAS1 in human tumors. A better understanding of its upstream regulation and downstream signaling could therefore provide insights to devise better strategies to target ZFAS1. The influences of genetic, epigenetic and environmental factors on ZFAS1 also warrant further investigation.

Pertinent to clinical practice, ZFAS1 might serve as an independent prognostic marker whose upregulation foreshadows a poor clinical outcome. Nevertheless, almost all studies did not include an independent cohort for validation. The prognostic and diagnostic performances of ZFAS1 against existing markers in different ethnic groups have also not yet been systemically assessed. Furthermore, the chemical stability of ZFAS1 in biological samples (e.g., serum) is also unclear. In future studies, the diagnostic and prognostic performance of ZFAS1 should be evaluated head-to-head with existing clinicopathological and serological markers in larger cohorts in order to accelerate its clinical utilization. Moreover, identification of small-molecule inhibitors of ZFAS1 through chemical library screening is also necessary to translate findings from basic science into clinical benefits.

Notes

Declarations

Authors’ contributions

CZ and MS conceived the idea. DD and ZM did the literature search. All the authors drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

This work was supported by Grants from the National Natural Science Foundation of China (Grant Number 81501346).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, People’s Republic of China
(2)
Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, People’s Republic of China
(3)
Department of Urology, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, People’s Republic of China

References

  1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in china. CA Cancer J Clin. 2015;66(2):115–32.View ArticleGoogle Scholar
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.View ArticlePubMedGoogle Scholar
  3. Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current challenges in cancer treatment. Clin Ther. 2016;38(7):1551–66.View ArticlePubMedGoogle Scholar
  4. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–64.View ArticlePubMedGoogle Scholar
  5. Veneziano D, Nigita G, Ferro A. Computational approaches for the analysis of ncRNA through deep sequencing techniques. Front Bioeng Biotechnol. 2015;3:77.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Theis M, Paszkowski-Rogacz M, Weisswange I, Chakraborty D, Buchholz F. Targeting human long noncoding transcripts by endoribonuclease-prepared sirnas. J Biomol Screen. 2015;20(8):1018–26.View ArticlePubMedGoogle Scholar
  7. Chen X, Yan GY. Novel human lncRNA-disease association inference based on lncRNA expression profiles. Bioinformatics. 2013;29(20):2617–24.View ArticlePubMedGoogle Scholar
  8. Chen X, Yan CC, Luo C, Ji W, Zhang Y, Dai Q. Constructing lncrna functional similarity network based on lncRNA-disease associations and disease semantic similarity. Sci Rep. 2013;5:11338.View ArticleGoogle Scholar
  9. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa A, Searle S, et al. Gencode: the reference human genome annotation for the encode project. Genome Res. 2012;22(9):1760–74.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Mercer TR, Dinger ME, Mattick JS. Long non-coding rnas: insights into functions. Nat Rev Genet. 2009;10(3):155–9.View ArticlePubMedGoogle Scholar
  11. Fatica A, Bozzoni I. Long non-coding rnas: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21.View ArticlePubMedGoogle Scholar
  12. Schmitt AM, Chang HY. Long noncoding rnas in cancer pathways. Cancer Cell. 2016;29(4):452–63.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Huarte M. The emerging role of lncrnas in cancer. Nat Med. 2015;21(11):1253–61.View ArticlePubMedGoogle Scholar
  14. Zhang S, Chen S, Yang G, Gu F, Li M, Zhong B, Hu J, Hoffman A, Chen M. Long noncoding rna hotair as an independent prognostic marker in cancer: a meta-analysis. PLoS ONE. 2014;9(8):e105538.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Xue Y, Teng YQ, Zhou JD, Rui YJ. Prognostic value of long noncoding rna malat1 in various carcinomas: evidence from nine studies. Tumour Biol. 2016;37(1):1211–5.View ArticlePubMedGoogle Scholar
  16. Askarian-Amiri ME, Crawford J, French JD, Smart CE, Smith MA, Clark MB, Ru K, Mercer TR, Thompson ER, Lakhani SR, et al. Snord-host rna ZFAS1 is a regulator of mammary development and a potential marker for breast cancer. RNA. 2011;17(5):878–91.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Liu F, Gao H, Li S, Ni X, Zhu Z. Long non-coding rna ZFAS1 correlates with clinical progression and prognosis in cancer patients. Oncotarget. 2017;8(37):61561–9.PubMedPubMed CentralGoogle Scholar
  18. Hansji H, Leung EY, Baguley BC, Finlay GJ, Cameron-Smith D, Figueiredo VC, Askarian-Amiri ME. ZFAS1: a long noncoding rna associated with ribosomes in breast cancer cells. Biol Direct. 2016;11(1):62.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Zhang Z, Weaver DL, Olsen D, deKay J, Peng Z, Ashikaga T, Evans MF. Long non-coding rna chromogenic in situ hybridisation signal pattern correlation with breast tumour pathology. J Clin Pathol. 2016;69(1):76–81.View ArticlePubMedGoogle Scholar
  20. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.View ArticlePubMedGoogle Scholar
  21. Lee J, Park HY, Kim WW, Lee SJ, Jeong JH, Kang SH, Jung JH, Chae YS. Biological function of long noncoding RNA snaR in Her2-positive breast cancer cells. Tumour Biol. 2017;39(6):1010428317707374.PubMedGoogle Scholar
  22. Fan S, Fan C, Liu N, Huang K, Fang X, Wang K. Down regulation of the long non-coding RNA ZFAS1 is associated with cell proliferation, migration and invasion in breast cancer. Mol Med Rep. 2018;17(5):6405–12.PubMedPubMed CentralGoogle Scholar
  23. McTyre E, Lucas JT, Helis C, Farris M, Soike M, Mott R, Laxton AW, Tatter SB, Lesser GJ, Strowd RE, et al. Outcomes for anaplastic glioma treated with radiation therapy with or without concurrent temozolomide. Am J Clin Oncol. 2018;41(8):813–19.View ArticlePubMedGoogle Scholar
  24. Zhang Y, Yu X, Chen L, Zhang Z, Feng S. Ezh2 overexpression is associated with poor prognosis in patients with glioma. Oncotarget. 2017;8(1):565–73.PubMedGoogle Scholar
  25. Gao K, Ji Z, She K, Yang Q, Shao L. Long non-coding RNA ZFAS1 is an unfavourable prognostic factor and promotes glioma cell progression by activation of the Notch signaling pathway. Biomed Pharmacother. 2017;87:555–60.View ArticlePubMedGoogle Scholar
  26. Lv QL, Chen SH, Zhang X, Sun B, Hu L, Qu Q, Huang YT, Wang GH, Liu YL, Zhang YY, et al. Upregulation of long noncoding RNA zinc finger antisense 1 enhances epithelial–mesenchymal transition in vitro and predicts poor prognosis in glioma. Tumour Biol. 2017;39(3):1010428317695022.PubMedGoogle Scholar
  27. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.View ArticlePubMedGoogle Scholar
  28. Brenner H, Bouvier AM, Foschi R, Hackl M, Larsen IK, Lemmens V, Mangone L, Francisci S. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the Eurocare study. Int J Cancer. 2012;131(7):1649–58.View ArticlePubMedGoogle Scholar
  29. Zheng R, Zeng H, Zhang S, Chen T, Chen W. National estimates of cancer prevalence in china, 2011. Cancer Lett. 2016;370(1):33–8.View ArticlePubMedGoogle Scholar
  30. Thorenoor N, Faltejskova-Vychytilova P, Hombach S, Mlcochova J, Kretz M, Svoboda M, Slaby O. Long non-coding rna ZFAS1 interacts with cdk1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. Oncotarget. 2016;7(1):622–37.View ArticlePubMedGoogle Scholar
  31. Wang W, Xing C. Upregulation of long noncoding rna ZFAS1 predicts poor prognosis and prompts invasion and metastasis in colorectal cancer. Pathol Res Pract. 2016;212(8):690–5.View ArticlePubMedGoogle Scholar
  32. Xie S, Quanxing G, Wang X, Sun X, Kang Y. Long non-coding RNA ZFAS1 sponges miR-484 to promote cell proliferation and invasion in colorectal cancer. Cell Cycle. 2018;17(2):154–61.View ArticlePubMedGoogle Scholar
  33. Fang C, Zan J, Yue B, Liu C, He C, Yan D. Long non-coding ribonucleic acid zinc finger antisense 1 promotes the progression of colonic cancer by modulating zeb1 expression. J Gastroenterol Hepatol. 2017;32(6):1204–11.View ArticlePubMedGoogle Scholar
  34. Mastoraki A, Benetou C, Mastoraki S, Papanikolaou IS, Danias N, Smyrniotis V, Arkadopoulos N. The role of surgery in the therapeutic approach of gastric cancer liver metastases. Indian J Gastroenterol. 2016;35(5):331–6.View ArticlePubMedGoogle Scholar
  35. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.View ArticlePubMedGoogle Scholar
  36. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374(9688):477–90.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Zhou H, Wang F, Chen H, Tan Q, Qiu S, Chen S, Jing W, Yu M, Liang C, Ye S, et al. Increased expression of long-noncoding rna ZFAS1 is associated with epithelial–mesenchymal transition of gastric cancer. Aging (Albany NY). 2016;8(9):2023–38.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Nie F, Yu X, Huang M, Wang Y, Xie M, Ma H, Wang Z, De W, Sun M. Long noncoding rna ZFAS1 promotes gastric cancer cells proliferation by epigenetically repressing klf2 and nkd2 expression. Oncotarget. 2017;8(24):38227–38.View ArticlePubMedGoogle Scholar
  39. Pan L, Liang W, Fu M, Huang ZH, Li X, Zhang W, Zhang P, Qian H, Jiang PC, Xu WR, et al. Exosomes-mediated transfer of long noncoding rna ZFAS1 promotes gastric cancer progression. J Cancer Res Clin Oncol. 2017;143(6):991–1004.View ArticlePubMedGoogle Scholar
  40. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–17.View ArticlePubMedGoogle Scholar
  41. Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Deng X, Chen H, Shen B, Peng C, et al. Amplification of long noncoding rna ZFAS1 promotes metastasis in Hepatocellular carcinoma. Cancer Res. 2015;75(15):3181–91.View ArticlePubMedGoogle Scholar
  42. Wang T, Ma S, Qi X, Tang X, Cui D, Wang Z, Chi J, Li P, Zhai B. Long noncoding rna znfx1-as1 suppresses growth of Hepatocellular carcinoma cells by regulating the methylation of mir-9. Onco Targets Ther. 2016;9:5005–14.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Cho KR, Shih Ie M. Ovarian cancer. Annu Rev Pathol. 2009;4:287–313.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Holmes D. Ovarian cancer: beyond resistance. Nature. 2015;527(7579):S217.View ArticlePubMedGoogle Scholar
  45. Xia B, Hou Y, Chen H, Yang S, Liu T, Lin M, Lou G. Long non-coding rna ZFAS1 interacts with mir-150-5p to regulate sp1 expression and ovarian cancer cell malignancy. Oncotarget. 2017;8(12):19534–46.PubMedPubMed CentralGoogle Scholar
  46. Liu R, Zeng Y, Zhou CF, Wang Y, Li X, Liu ZQ, Chen XP, Zhang W, Zhou HH. Long noncoding rna expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients. Sci Rep. 2017;7(1):18.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Wei YH, Fu Y, Luo HJ, Li R, Li HY, Zhang Z, Zhu YH. GaoY, Liu XL. Higher expression of ZFAS1 is associated with poor prognosis in malignant melanoma and promotes cell proliferation and invasion. Int. J Clin Exp Pathol. 2017;10(4):4640–6.Google Scholar
  48. Tian FM, Meng FQ, Wang XB. Overexpression of long-noncoding rna ZFAS1 decreases survival in human NSCLC patients. Eur Rev Med Pharmacol Sci. 2016;20(24):5126–31.PubMedGoogle Scholar
  49. Liu G, Wang L, Han H, Li Y, Lu S, Li T, Cheng C. Lncrna ZFAS1 promotes growth and metastasis by regulating bmi1 and zeb2 in osteosarcoma. Am J Cancer Res. 2017;7(7):1450–62.PubMedPubMed CentralGoogle Scholar
  50. Shi H, Liu Z, Pei D, Jiang Y, Zhu H, Chen B. Development and validation of nomogram based on lncrna ZFAS1 for predicting survival in lymph node-negative esophageal squamous cell carcinoma patients. Oncotarget. 2017;8(35):59048–57.PubMedPubMed CentralGoogle Scholar
  51. Guo H, Wu L, Zhao P, Feng A. Overexpression of long non-coding rna zinc finger antisense 1 in acute myeloid leukemia cell lines influences cell growth and apoptosis. Exp Ther Med. 2017;14(1):647–51.View ArticlePubMedPubMed CentralGoogle Scholar
  52. Baytak E, Gong Q, Akman B, Yuan H, Chan WC, Kucuk C. Whole transcriptome analysis reveals dysregulated oncogenic lncRNAs in natural killer/t-cell lymphoma and establishes mir155hg as a target of prdm1. Tumour Biol. 2017;39(5):1010428317701648.View ArticlePubMedGoogle Scholar
  53. De Craene B, Berx G. Regulatory networks defining emt during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110.View ArticlePubMedGoogle Scholar
  54. Nakaya Y, Sheng G. Emt in developmental morphogenesis. Cancer Lett. 2013;341(1):9–15.View ArticlePubMedGoogle Scholar
  55. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science. 2013;342(6159):1234850.View ArticlePubMedGoogle Scholar
  56. Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166(1):21–45.View ArticlePubMedGoogle Scholar
  57. Santamaria PG, Moreno-Bueno G, Portillo F, Cano A. Emt: present and future in clinical oncology. Mol Oncol. 2017;11(7):718–38.View ArticlePubMedPubMed CentralGoogle Scholar
  58. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–52.View ArticlePubMedPubMed CentralGoogle Scholar
  59. Guo LL, Song CH, Wang P, Dai LP, Zhang JY, Wang KJ. Competing endogenous RNA networks and gastric cancer. World J Gastroenterol. 2015;21(41):11680–7.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement